{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:46:29Z","timestamp":1783637189121,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,20]]},"DOI":"10.7759\/cureus.43821","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T03:24:10Z","timestamp":1692588250000},"source":"Crossref","is-referenced-by-count":6,"title":["Mirtazapine: A One-Stop Strategy for Treatment of Opioid Withdrawal Symptoms"],"prefix":"10.7759","author":[{"given":"Elisha","family":"Lalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raakhi","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam A","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecil","family":"Kumfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaila","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Centers for Medicare & Medicaid Services. Ongoing emergencies & disasters. (2022). Accessed: October 14, 2022: https:\/\/www.cms.gov\/About-CMS\/Agency-Information\/Emergency\/EPRO\/Current-Emergencies\/Ongoing-emergencies."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-018-0060-z","article-title":"Response dynamics of midbrain dopamine neurons and serotonin neurons to heroin, nicotine, cocaine, and MDMA","volume":"4","author":"Wei C","year":"2018","unstructured":"Wei C, Han X, Weng D, Feng Q, Qi X, Li J, Luo M. Response dynamics of midbrain dopamine neurons and serotonin neurons to heroin, nicotine, cocaine, and MDMA. Cell Discov. 2018, 4:60. 10.1038\/s41421-018-0060-z","journal-title":"Cell Discov"},{"key":"ref3","article-title":"Mirtazapine","author":"Jilani TN","year":"2022","unstructured":"Jilani TN, Gibbons JR, Faizy RM, Saadabadi A. Mirtazapine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1213\/01.ane.0000289636.09841.bc","article-title":"Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting","volume":"106","author":"Chen CC","year":"2008","unstructured":"Chen CC, Lin CS, Ko YP, Hung YC, Lao HC, Hsu YW. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008, 106:109-13. 10.1213\/01.ane.0000289636.09841.bc","journal-title":"Anesth Analg"},{"key":"ref5","article-title":"Serotonin receptor physiology: relation to emesis","volume":"44","author":"Hasler WL","year":"1999","unstructured":"Hasler WL. Serotonin receptor physiology: relation to emesis. Dig Dis Sci. 1999, 44:108S-13S.","journal-title":"Dig Dis Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.03.015","article-title":"Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting","volume":"30","author":"Pae CU","year":"2006","unstructured":"Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry. 2006, 30:1143-5. 10.1016\/j.pnpbp.2006.03.015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S125743","article-title":"Mirtazapine for symptom control in refractory gastroparesis","volume":"11","author":"Malamood M","year":"2017","unstructured":"Malamood M, Roberts A, Kataria R, Parkman HP, Schey R. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017, 11:1035-41. 10.2147\/DDDT.S125743","journal-title":"Drug Des Devel Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-016-0110-2","article-title":"Newest drugs for chronic unexplained nausea and vomiting","volume":"14","author":"Hasler WL","year":"2016","unstructured":"Hasler WL. Newest drugs for chronic unexplained nausea and vomiting. Curr Treat Options Gastroenterol. 2016, 14:371-85. 10.1007\/s11938-016-0110-2","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1381\/0960892053923923","article-title":"Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass","volume":"15","author":"Teixeira FV","year":"2005","unstructured":"Teixeira FV, Novaretti TM, Pilon B, Pereira PG, Breda MF. Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass. Obes Surg. 2005, 15:707-9. 10.1381\/0960892053923923","journal-title":"Obes Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13030-021-00205-2","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome","volume":"15","author":"Khalilian A","year":"2021","unstructured":"Khalilian A, Ahmadimoghaddam D, Saki S, Mohammadi Y, Mehrpooya M. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome. Biopsychosoc Med. 2021, 15:3. 10.1186\/s13030-021-00205-2","journal-title":"Biopsychosoc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318209cef2","article-title":"Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine","volume":"34","author":"Spiegel DR","year":"2011","unstructured":"Spiegel DR, Kolb R. Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine. Clin Neuropharmacol. 2011, 34:36-8. 10.1097\/WNF.0b013e318209cef2","journal-title":"Clin Neuropharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5056\/jnm19166","article-title":"Depression and structural factors are associated with symptoms in patients of irritable bowel syndrome with diarrhea","volume":"26","author":"Lu J","year":"2020","unstructured":"Lu J, Shi L, Huang D, et al.. Depression and structural factors are associated with symptoms in patients of irritable bowel syndrome with diarrhea. J Neurogastroenterol Motil. 2020, 26:505-13. 10.5056\/jnm19166","journal-title":"J Neurogastroenterol Motil"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_46_17","article-title":"Anxiety and depression in irritable bowel syndrome","volume":"39","author":"Banerjee A","year":"2017","unstructured":"Banerjee A, Sarkhel S, Sarkar R, Dhali GK. Anxiety and depression in irritable bowel syndrome. Indian J Psychol Med. 2017, 39:741-5. 10.4103\/IJPSYM.IJPSYM_46_17","journal-title":"Indian J Psychol Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.08.013","article-title":"Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside","volume":"136","author":"Graves SM","year":"2012","unstructured":"Graves SM, Rafeyan R, Watts J, Napier TC. Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. Pharmacol Ther. 2012, 136:343-53. 10.1016\/j.pharmthera.2012.08.013","journal-title":"Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802183921","article-title":"Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats","volume":"34","author":"Kang L","year":"2008","unstructured":"Kang L, Wang D, Li B, Hu M, Zhang P, Li J. Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. Am J Drug Alcohol Abuse. 2008, 34:541-52. 10.1080\/00952990802183921","journal-title":"Am J Drug Alcohol Abuse"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01421-5","article-title":"Mirtazapine for agitation in dementia: moving forward","volume":"1016","author":"Lanctot KL","year":"2021","unstructured":"Lanctot KL, Herrmann N. Mirtazapine for agitation in dementia: moving forward. Lancet. 2021, 1016:0140-6736. 10.1016\/S0140-6736(21)01421-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01210-1","article-title":"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial","volume":"398","author":"Banerjee S","year":"2021","unstructured":"Banerjee S, High J, Stirling S, et al.. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021, 398:1487-97. 10.1016\/S0140-6736(21)01210-1","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13r01525","article-title":"A review of therapeutic uses of mirtazapine in psychiatric and medical conditions","volume":"15","author":"Alam A","year":"2013","unstructured":"Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord. 2013, 15:10.4088\/PCC.13r01525","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2007.01778.x","article-title":"Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression","volume":"62","author":"Kim SW","year":"2008","unstructured":"Kim SW, Shin IS, Kim JM, et al.. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008, 62:75-83. 10.1111\/j.1440-1819.2007.01778.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2017.06.003","article-title":"Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors","volume":"29","author":"Sinha P","year":"2017","unstructured":"Sinha P, Shetty DJ, Bairy LK, Andrade C. Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors. Asian J Psychiatr. 2017, 29:148-53. 10.1016\/j.ajp.2017.06.003","journal-title":"Asian J Psychiatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048371","article-title":"Antidepressant-induced jitteriness\/anxiety syndrome: systematic review","volume":"194","author":"Sinclair LI","year":"2009","unstructured":"Sinclair LI, Christmas DM, Hood SD, et al.. Antidepressant-induced jitteriness\/anxiety syndrome: systematic review. Br J Psychiatry. 2009, 194:483-90. 10.1192\/bjp.bp.107.048371","journal-title":"Br J Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1998.tb09993.x","article-title":"Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study","volume":"97","author":"Srisurapanont M","year":"1998","unstructured":"Srisurapanont M, Jarusuraisin N. Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study. Acta Psychiatr Scand. 1998, 97:233-5. 10.1111\/j.1600-0447.1998.tb09993.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/bs.podrm.2018.01.002","article-title":"Mirtazapine","volume":"43","author":"Al-Majed A","year":"2018","unstructured":"Al-Majed A, Bakheit AH, Alharbi RM, Abdel Aziz HA. Mirtazapine. Profiles Drug Subst Excip Relat Methodol. 2018, 43:209-54. 10.1016\/bs.podrm.2018.01.002","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"key":"ref24","article-title":"The effects of mirtazapine on sleep in patients with major depressive disorder","volume":"24","author":"Dolder CR","year":"2012","unstructured":"Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012, 24:215-24.","journal-title":"Ann Clin Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116681399","article-title":"Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial","volume":"31","author":"Karsten J","year":"2017","unstructured":"Karsten J, Hagenauw LA, Kamphuis J, Lancel M. Low doses of mirtazapine or quetiapine for transient insomnia: a randomised, double-blind, cross-over, placebo-controlled trial. J Psychopharmacol. 2017, 31:327-37. 10.1177\/0269881116681399","journal-title":"J Psychopharmacol"},{"key":"ref26","article-title":"Psychotropic-induced weight gain: a review of management strategies","volume":"53","author":"White W","year":"2013","unstructured":"White W, Elmore L, Luthin D, Cates M. Psychotropic-induced weight gain: a review of management strategies. Consultant. 2013, 53:","journal-title":"Consultant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/IJPC.IJPC_17_17","article-title":"Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia","volume":"23","author":"Kumar N","year":"2017","unstructured":"Kumar N, Barai S, Gambhir S, Rastogi N. Effect of mirtazapine on gastric emptying in patients with cancer-associated anorexia. Indian J Palliat Care. 2017, 23:335-7. 10.4103\/IJPC.IJPC_17_17","journal-title":"Indian J Palliat Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/1049909109345685","article-title":"Phase II trial of mirtazapine for cancer-related cachexia and anorexia","volume":"27","author":"Riechelmann RP","year":"2010","unstructured":"Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010, 27:106-10. 10.1177\/1049909109345685","journal-title":"Am J Hosp Palliat Care"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/neuro.23.003.2009","article-title":"Neurobiology of inflammation-associated anorexia","volume":"3","author":"Gautron L","year":"2009","unstructured":"Gautron L, Lay\u00e9 S. Neurobiology of inflammation-associated anorexia. Front Neurosci. 2009, 3:59. 10.3389\/neuro.23.003.2009","journal-title":"Front Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: a systematic review","volume":"77","author":"Kouwenhoven TA","year":"2017","unstructured":"Kouwenhoven TA, van de Kerkhof PC, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: a systematic review. J Am Acad Dermatol. 2017, 77:1068-1073.e7. 10.1016\/j.jaad.2017.08.025","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1630702","article-title":"Defining the role of mirtazapine in the treatment of refractory pruritus","volume":"32","author":"Fawaz B","year":"2021","unstructured":"Fawaz B, Chamseddin BH, Griffin JR. Defining the role of mirtazapine in the treatment of refractory pruritus. J Dermatolog Treat. 2021, 32:132-6. 10.1080\/09546634.2019.1630702","journal-title":"J Dermatolog Treat"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02473-3","article-title":"Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study","volume":"52","author":"Gholyaf M","year":"2020","unstructured":"Gholyaf M, Sheikh V, Yasrebifar F, Mohammadi Y, Mirjalili M, Mehrpooya M. Effect of mirtazapine on pruritus in patients on hemodialysis: a cross-over pilot study. Int Urol Nephrol. 2020, 52:1155-65. 10.1007\/s11255-020-02473-3","journal-title":"Int Urol Nephrol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6030073","article-title":"Mirtazapine for the treatment of chronic pruritus","volume":"6","author":"Khanna R","year":"2019","unstructured":"Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG. Mirtazapine for the treatment of chronic pruritus. Medicines (Basel). 2019, 6:73. 10.3390\/medicines6030073","journal-title":"Medicines (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aen241","article-title":"Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus","volume":"101","author":"Sheen MJ","year":"2008","unstructured":"Sheen MJ, Ho ST, Lee CH, Tsung YC, Chang FL, Huang ST. Prophylactic mirtazapine reduces intrathecal morphine-induced pruritus. Br J Anaesth. 2008, 101:711-5. 10.1093\/bja\/aen241","journal-title":"Br J Anaesth"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/s0885-3924(02)00645-0","article-title":"Mirtazapine for pruritus","volume":"25","author":"Davis MP","year":"2003","unstructured":"Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. Mirtazapine for pruritus. J Pain Symptom Manage. 2003, 25:288-91. 10.1016\/s0885-3924(02)00645-0","journal-title":"J Pain Symptom Manage"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.045","article-title":"Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study","volume":"50","author":"Hundley JL","year":"2004","unstructured":"Hundley JL, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004, 50:889-91. 10.1016\/j.jaad.2004.01.045","journal-title":"J Am Acad Dermatol"},{"key":"ref37","article-title":"Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study","volume":"2","author":"Uccellini D","year":"2006","unstructured":"Uccellini D, Grampa G, La Spina I, et al.. Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. Neuropsychiatr Dis Treat. 2006, 2:95-100.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.53.5.1154-a","article-title":"Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias","volume":"53","author":"Pact V","year":"1999","unstructured":"Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology. 1999, 53:1154. 10.1212\/wnl.53.5.1154-a","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2012.696527","article-title":"Mirtazapine in comorbid major depression and alcohol dependence: an open-label trial","volume":"8","author":"Cornelius JR","year":"2012","unstructured":"Cornelius JR, Douaihy AB, Clark DB, Chung T, Wood DS, Daley D. Mirtazapine in comorbid major depression and alcohol dependence: an open-label trial. J Dual Diagn. 2012, 8:200-4. 10.1080\/15504263.2012.696527","journal-title":"J Dual Diagn"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s11469-021-00547-6","article-title":"Effect of mirtazapine on craving in cocaine-dependent patients","volume":"4","author":"Nanni-Alvarado R","year":"2022","unstructured":"Nanni-Alvarado R, Gonzalez M, Lima C, Mar\u00edn-Navarrete R, Barbosa-M\u00e9ndez S, Salazar-Ju\u00e1rez A. Effect of mirtazapine on craving in cocaine-dependent patients. Int J Ment Health Addiction. 2022, 4:2770-86. 10.1007\/s11469-021-00547-6","journal-title":"Int J Ment Health Addiction"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: a randomized controlled trial","volume":"68","author":"Colfax GN","year":"2011","unstructured":"Colfax GN, Santos GM, Das M, et al.. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011, 68:1168-75. 10.1001\/archgenpsychiatry.2011.124","journal-title":"Arch Gen Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial","volume":"77","author":"Coffin PO","year":"2020","unstructured":"Coffin PO, Santos GM, Hern J, et al.. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020, 77:246-55. 10.1001\/jamapsychiatry.2019.3655","journal-title":"JAMA Psychiatry"},{"key":"ref43","unstructured":"ClinicalTrials.gov. Mirtazapine as a treatment for co-occurring opioid and ATS dependence in Malaysia. (2015). Accessed: 2023: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02541526."},{"key":"ref44","article-title":"Opioid withdrawal","author":"Shah M","year":"2023","unstructured":"Shah M, Huecker MR. Opioid withdrawal. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s3201","article-title":"The efficacy of mirtazapine in agitated patients with Alzheimer's disease: a 12-week open-label pilot study","volume":"4","author":"Cakir S","year":"2008","unstructured":"Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer's disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008, 4:963-6. 10.2147\/ndt.s3201","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","article-title":"A review of the pharmacological and clinical profile of mirtazapine","volume":"7","author":"Anttila SA","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001, 7:249-64. 10.1111\/j.1527-3458.2001.tb00198.x","journal-title":"CNS Drug Rev"},{"key":"ref47","article-title":"Withdrawal syndromes","author":"Gupta M","year":"2023","unstructured":"Gupta M, Gokarakonda SB, Attia FN. Withdrawal syndromes. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178338-mirtazapine-a-one-stop-strategy-for-treatment-of-opioid-withdrawal-symptoms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:28Z","timestamp":1707509008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178338-mirtazapine-a-one-stop-strategy-for-treatment-of-opioid-withdrawal-symptoms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.43821","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,20]]}}}